RLAY Quote, Financials, Valuation and Earnings

Arrowhead Pharmaceuticals, Inc. has a net margin of -10395.13% compared to Relay Therapeutics, Inc.'s net margin of 6.29%. Relay Therapeutics, Inc.'s return on equity of -41.21% beat Arrowhead Pharmaceuticals, Inc.'s return on equity of 7.7%.

Relay Therapeutics, Inc. has a consensus price target of $14.60, signalling upside risk potential of 75.69%. On the other hand Arrowhead Pharmaceuticals, Inc. has an analysts' consensus of $66.00 which suggests that it could fall by -5.49%. Given that Relay Therapeutics, Inc. has higher upside potential than Arrowhead Pharmaceuticals, Inc., analysts believe Relay Therapeutics, Inc. is more attractive than Arrowhead Pharmaceuticals, Inc..

Relay Therapeutics, Inc. has a beta of 1.501, which suggesting that the stock is 50.076% more volatile than S&P 500. In comparison Arrowhead Pharmaceuticals, Inc. has a beta of 1.279, suggesting its more volatile than the S&P 500 by 27.862%.

Relay Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arrowhead Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Relay Therapeutics, Inc. pays -- of its earnings as a dividend. Arrowhead Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Relay Therapeutics, Inc. quarterly revenues are --, which are smaller than Arrowhead Pharmaceuticals, Inc. quarterly revenues of $256.5M. Relay Therapeutics, Inc.'s net income of -$74.1M is lower than Arrowhead Pharmaceuticals, Inc.'s net income of $16.1M. Notably, Relay Therapeutics, Inc.'s price-to-earnings ratio is -- while Arrowhead Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Relay Therapeutics, Inc. is 169.12x versus 11.29x for Arrowhead Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Insmed, Inc. has a net margin of -10395.13% compared to Relay Therapeutics, Inc.'s net margin of -259.95%. Relay Therapeutics, Inc.'s return on equity of -41.21% beat Insmed, Inc.'s return on equity of -193.23%.

Relay Therapeutics, Inc. has a consensus price target of $14.60, signalling upside risk potential of 75.69%. On the other hand Insmed, Inc. has an analysts' consensus of $214.78 which suggests that it could grow by 21.6%. Given that Relay Therapeutics, Inc. has higher upside potential than Insmed, Inc., analysts believe Relay Therapeutics, Inc. is more attractive than Insmed, Inc..

Relay Therapeutics, Inc. has a beta of 1.501, which suggesting that the stock is 50.076% more volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.015, suggesting its more volatile than the S&P 500 by 1.49%.

Relay Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Relay Therapeutics, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.

Relay Therapeutics, Inc. quarterly revenues are --, which are smaller than Insmed, Inc. quarterly revenues of $142.3M. Relay Therapeutics, Inc.'s net income of -$74.1M is higher than Insmed, Inc.'s net income of -$370M. Notably, Relay Therapeutics, Inc.'s price-to-earnings ratio is -- while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Relay Therapeutics, Inc. is 169.12x versus 75.23x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -10395.13% compared to Relay Therapeutics, Inc.'s net margin of 31.72%. Relay Therapeutics, Inc.'s return on equity of -41.21% beat Eli Lilly & Co.'s return on equity of 106.26%.

Relay Therapeutics, Inc. has a consensus price target of $14.60, signalling upside risk potential of 75.69%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,093.22 which suggests that it could grow by 2.01%. Given that Relay Therapeutics, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Relay Therapeutics, Inc. is more attractive than Eli Lilly & Co..

Relay Therapeutics, Inc. has a beta of 1.501, which suggesting that the stock is 50.076% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Relay Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.56% to investors and pays a quarterly dividend of $1.50 per share. Relay Therapeutics, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Relay Therapeutics, Inc. quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Relay Therapeutics, Inc.'s net income of -$74.1M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Relay Therapeutics, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 53.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Relay Therapeutics, Inc. is 169.12x versus 16.44x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Lantheus Holdings, Inc. has a net margin of -10395.13% compared to Relay Therapeutics, Inc.'s net margin of 7.23%. Relay Therapeutics, Inc.'s return on equity of -41.21% beat Lantheus Holdings, Inc.'s return on equity of 14.66%.

Relay Therapeutics, Inc. has a consensus price target of $14.60, signalling upside risk potential of 75.69%. On the other hand Lantheus Holdings, Inc. has an analysts' consensus of $82.43 which suggests that it could grow by 23.9%. Given that Relay Therapeutics, Inc. has higher upside potential than Lantheus Holdings, Inc., analysts believe Relay Therapeutics, Inc. is more attractive than Lantheus Holdings, Inc..

Relay Therapeutics, Inc. has a beta of 1.501, which suggesting that the stock is 50.076% more volatile than S&P 500. In comparison Lantheus Holdings, Inc. has a beta of -0.102, suggesting its less volatile than the S&P 500 by 110.17%.

Relay Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lantheus Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Relay Therapeutics, Inc. pays -- of its earnings as a dividend. Lantheus Holdings, Inc. pays out -- of its earnings as a dividend.

Relay Therapeutics, Inc. quarterly revenues are --, which are smaller than Lantheus Holdings, Inc. quarterly revenues of $384M. Relay Therapeutics, Inc.'s net income of -$74.1M is lower than Lantheus Holdings, Inc.'s net income of $27.8M. Notably, Relay Therapeutics, Inc.'s price-to-earnings ratio is -- while Lantheus Holdings, Inc.'s PE ratio is 27.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Relay Therapeutics, Inc. is 169.12x versus 3.04x for Lantheus Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.